Optimal Dose https://validator.w3.org/feed/docs/rss2.html Weekly News 19 September to 25 September 2026 Weekly News 19 September to 25 September 2026 Iza-bren granted BTD in China for the treatment of mTNBC Telix and ITM join forces to create a radiopharmaceutical powerhouse BoomRay enters exclusive global license agreement with Novartis for a novel radioligand therapy asset SOTIO advances SOT106 with dual FDA designations for Sarcoma PADCEV + Keytruda receives positive CHMP opinion for resectable MIBC Enhertu receives CHMP recommendation for adjuvant treatment of HER2-positive early Breast cancer Optimal Dose – CAR-T Digest (August 2020) Sino Biopharmaceutical announces NDA acceptance for TQB2102 in HER2-low Breast cancer in China ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer SYS6010 received NMPA BTD in China for actionable genomic alteration-negative non-squamous NSCLC Weekly News 12 September to 18 September 2026 Weekly News 12 September to 18 September 2026 Escugen and Sovran expand collaboration to co-develop a novel bispecific ADC Hengrui’s HER3 ADC, SHR-A2009 for injection, included in China’s Breakthrough Therapy list for NSCLC Enhertu and Datroway approved in Japan for two new 1L indications in metastatic Breast cancer Cellbion and AHN-GOOK Pharmaceutical announced a collaboration for the joint development of next-generation radiopharmaceuticals Adlai Nortye announced the first patient dosing in Australia and U.S. FDA IND clearance for AN4035 Weekly News 05 September to 11 September 2026 Weekly News 05 September to 11 September 2026 ITM and SpiroChem announced a strategic discovery collaboration to expand ITM’s radiopharmaceutical pipeline Adagene announced a milestone with Exelixis supporting the advancement of SAFEbody ADC candidates Acepodia announces FDA clearance of IND application for ACE723, a novel dual-payload ADC InnoCare announced approval in China to initiate clinical trials of ICP-B381, a novel PSMA/STEAP1-targeting bispecific ADC Weekly News 03 October to 09 October 2026 Weekly News 03 October to 09 October 2026 Enhertu approved in China for HER2-positive early Breast cancer with residual disease AstraZeneca and Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway plus Ivonescimab across multiple tumor types [²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors Weekly News 29 August to 04 September 2026 Weekly News 29 August to 04 September 2026 DualityBio enters global collaboration with Roche to develop next-generation ADCs using the DUPAC novel-payload platform HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy IDEAYA Biosciences’ IDE849 advances to a phase 3 registrational trial following a successful FDA type C meeting for ES-SCLC Hansoh Pharmaceutical’s HS-20093 injection marketing authorization application for SCLC accepted by China’s NMPA SYS6010 granted BTD by the NMPA in China for the treatment of patients with recurrent or metastatic HNSCC Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S. BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer Weekly News 26 September to 02 October 2026 Weekly News 26 September to 02 October 2026 Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations in cancer Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer Dong-A ST and Galux entered a research collaboration to develop AI-designed antibodies for ADC therapeutics Monthly Digest – October 2026 Monthly Digest – October 2026